We are live on ! Find out more
APEN

Apollo Endosurgery, Inc.

Delisted

APEN was delisted on the 3rd of April, 2023.

53 hedge funds and large institutions have $174M invested in Apollo Endosurgery, Inc. in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,354% more call options, than puts

Call options by funds: $11.5M | Put options by funds: $136K

150% more funds holding in top 10

Funds holding in top 10: 25 (+3)

59% more capital invested

Capital invested by funds: $110M → $174M (+$64.7M)

50% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 14

16% less funds holding

Funds holding: 6353 (-10)

59% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 17

Holders
53
Holders Change
-10
Holders Change %
-15.87%
% of All Funds
0.91%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.09%
New
7
Increased
21
Reduced
14
Closed
17
Calls
$11.5M
Puts
$136K
Net Calls
+$11.4M
Net Calls Change
+$5.04M
Name Holding Trade Value Shares
Change
Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$21.9M +$1.39M +250,896 +7%
CI
2
CPMG Inc
Texas
$21.8M +$324K +58,416 +1%
SCM
3
Stonepine Capital Management
Oregon
$15.6M +$3.72M +670,632 +31%
Citigroup
4
Citigroup
New York
$11.1M +$2.28M +410,438 +26%
ACM
5
Archon Capital Management
Washington
$10.2M +$4.92M +887,388 +93%
GS
6
Gagnon Securities
New York
$9.84M -$55.5K -10,015 -0.6%
DM
7
Deerfield Management
New York
$9.64M
Vanguard Group
8
Vanguard Group
Pennsylvania
$7.5M +$85.4K +15,400 +1%
GA
9
Gagnon Advisors
New York
$7.33M
SCM
10
Soleus Capital Management
Connecticut
$6.26M -$11.8M -2,131,843 -65%
SCM
11
Silverarc Capital Management
Massachusetts
$6.26M +$340K +61,327 +6%
Russell Investments Group
12
Russell Investments Group
United Kingdom
$5.25M +$5.28M +952,732 New
Goldman Sachs
13
Goldman Sachs
New York
$4.94M +$685K +123,495 +16%
AIC
14
AWM Investment Company
New York
$4.57M +$2.62M +473,288 +133%
PHP
15
Parkman Healthcare Partners
Connecticut
$3.62M +$42.6K +7,690 +1%
BlackRock
16
BlackRock
New York
$3.15M +$766K +138,134 +32%
PGM
17
Parian Global Management
New York
$2.9M -$1.14M -205,840 -28%
ACM
18
AIGH Capital Management
Maryland
$2.8M +$2.82M +508,536 New
GGHC
19
Gilder Gagnon Howe & Co
New York
$2.54M -$7.22K -1,302 -0.3%
PVI
20
Pura Vida Investments
New York
$2.35M
EIM
21
Essex Investment Management
Massachusetts
$2.21M +$61.9K +11,159 +3%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$1.89M +$355K +63,995 +23%
Assenagon Asset Management
23
Assenagon Asset Management
Luxembourg
$1.15M
Northern Trust
24
Northern Trust
Illinois
$1.06M +$68.8K +12,399 +7%
BCM
25
Bridgeway Capital Management
Texas
$965K -$322K -58,000 -25%

APEN Hedge Fund Activity: Q3 2022 in Review

53 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Apollo Endosurgery, Inc. (APEN) for Q3 2022, worth a combined $174M — up 59% from $110M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of APEN and 7 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 21 added.

The largest buyer was Russell Investments Group, opening a new position worth an estimated $5.28M. The largest seller was Soleus Capital Management, cutting an estimated $11.8M.

  • 53 institutional investors held Apollo Endosurgery, Inc. (APEN) as of Q3 2022, down from 63 in Q2 2022.
  • Funds reported $174M of Apollo Endosurgery, Inc. stock for Q3 2022, up 59% quarter-over-quarter.
  • 7 funds opened new Apollo Endosurgery, Inc. positions in Q3 2022 and 17 closed out, a net change of -10 holders.
  • The largest Apollo Endosurgery, Inc. buyer in Q3 2022 was Russell Investments Group, an estimated $5.28M added.
  • The largest Apollo Endosurgery, Inc. seller in Q3 2022 was Soleus Capital Management, an estimated $11.8M sold.

Based on aggregated 13F filings for Q3 2022.